title: Biologics debate heats up between FDA, NCCN.
authors: John
authors: J
authors: Carroll
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000191:economics; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001688:Biological Products / Q000009:adverse effects / Q000191:economics*; D006801:Humans; D012952:Societies; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D000068258:Bevacizumab